NCT02026401 - Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Primary Biliary Cirrhosis

Interventions

BIOLOGICAL

NGM282

BIOLOGICAL

Placebo

Trial Locations (17)

NGM Clinical Study Site 103, Phoenix

NGM Clinical Study Site 108, Coronado

NGM Clinical Study Site 101, Detroit

NGM Clinical Study Site 105, Durham

NGM Clinical Study Site 102, Dallas

NGM Clinical Study Site 113, San Antonio

NGM Clinical Study Site 104, Richmond

NGM Clinical Study Site 602, Sydney

NGM Clinical Study Site 606, Sydney

NGM Clinical Study Site 609, Sydney

NGM Clinical Study Site 611, Sydney

NGM Clinical Study Site 614, Brisbane

NGM Clinical Study Site 607, Adelaide

NGM Clinical Study Site 608, Adelaide

NGM Clinical Study Site 601, Melbourne

NGM Clinical Study Site 604, Melbourne

NGM Clinical Study Site 613, Melbourne